Pfizer Stock News

Sierra Capital LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 28.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,120 shares of the biopharmaceutical companys stock after selling 1,664 shares during the period. Sierra Capital LLCs holdings in Pfizer were worth $177,000 at the end of the most recent quarter. Other institutional investors []

Due to limited supply, the Middlesex London Health Unit will be prioritizing the Pfizer-BioNTech vaccine for people under 29 years old.

A three-dose course of AstraZeneca Plc''s (NASDAQ: AZN ) COVID-19 vaccine is effective against the omicron coronavirus variant , data from an Oxford University lab study shows. Findings from the study, yet to be published in a peer-reviewed medical journal, match those from Pfizer Inc (NYSE: PFE ) - BioNTech SE (NASDAQ: BNTX ), which have also found a third dose Full story available on Benzinga.com

The Renfrew County and District Health Unit says supplies of the Pfizer vaccine for COVID-19 will “become limited” across all local vaccine clinics as of today. In a statement, the health unit said supplies of Pfizer will be reserved for individuals under the age of 30 “until further notice.” Anyone over 30 will be offered […]

Pfizer''s COVID-19 antiviral pill will already have some competition in the US: The Food and Drug Administration has given emergency use authorization for Merck''s Molnupiravir pill.

Cook County Board President Toni Preckwinkle | Pat Nabong/Sun-Times file There’s an exemption for people picking up takeout food. Cook County, following Chicago’s lead, announced Thursday it will be implementing a COVID-19 vaccination mandate for customers of indoor settings where food or drink are served for on-premises consumption, like restaurants, bars, and entertainment venues, and in fitness facilities. The county’s vaccine mandate will begin Jan. 3. Under the order issued by the county’s Health Department, businesses must require any individual 5 years of age and older to show proof that they are fully vaccinated against COVID-19 with an approved vaccine in order to enter the establishment. Customers must be fully vaccinated, meaning they are two weeks removed from their second dose of the Pfizer or Moderna vaccines or a single dose of the Johnson & Johnson vaccine. Booster shots are not required, though Health Department officials urge people to get boosted. Businesses must also require patrons age 16 and older to show identification — including but not limited to driver’s license, passport, government ID, work or school ID — with information that corresponds to the vaccination proof.

An official from the United States Food and Drug Administration (FDA) said on Thursday that both Pfizer''s and Merck''s antiviral pills against COVID-19 are effective against the Omicron variant

MISE & Agrave; DAY The COVID-19 pill from Merck laboratory, intended for high-risk adults, was urgently authorized Thursday by the United States Medicines Agency (FDA), the day after authorization of a similar pill developed by Pfizer. & nbsp; Today''s approval adds a new treatment for COVID-19, in the form of a pill that can be [] The post Merck''s COVID-19 pill cleared in US first appeared on The Bobr Times .

Stocks Analysis by Zacks Investment Research covering: Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc. Read Zacks Investment Research''s latest article on Investing.com

European markets ended Thursday''s session with strong gains on a string of positive news regarding COVID-19 vaccines and treatments. The US granted both Pfizer''s and Merck''s pills emergenc…

Pfizer scientists in Groton played a critical role in development of new COVID-19 pill

The post FDA Approves Mercks Antiviral Pill For Emergency Use appeared on BitcoinEthereumNews.com . Topline The Food and Drug Administration approved Mercks antiviral pill, molnupiravir, for emergency use to treat Covid-19, it said Thursday, a day after it greenlit Pfizers antiviral drug, adding new

Pfizer''s COVID-19 antiviral pill will already have some competition in the US. As the Associated Press reports , the Food and Drug Administration has given emergency use authorization for Merck''s Molnupiravir pill. The treatment limits replication of SARS-CoV-2 by inserting "errors" in the virus'' genetic code while an infection is relatively young, ideally preventing mild or moderate cases from becoming severe in high-risk patients. The medicine might not get as much use as Pfizer''s Paxlovid, however. Merck''s offering will only be available to those 18 years or older versus 12 years for Pfizer''s, as there are concerns it might affect bone and cartilage development in younger patients. There are also warnings against using it during pregnancy or while attempting to conceive the FDA said people should use birth control both during and after treatment, with women waiting days and men waiting three months. Molnupiravir also doesn''t appear to be as effective as Paxlovid. While Pfizer''s solution reduced hospitalization and death by as much as 90 percent, Merck''s only managed 30 percent.

The U.S. Food and Drug Administration has authorized the second antiviral pill to treat COVID-19 at home. The medicine, called molnupiravir and made by Merck and Ridgeback Biotherapeutics, is taken twice a day for five days. Merck says it will have 10 million packs available by the end of the month. These new antiviral pills could totally change how people treat COVID infections at home, since the only FDA-authorized treatment for non-hospitalized COVID-19 patients is monoclonal antibodies, which typically require an intravenous infusion. The agency authorized Pfizer''s Paxlovid treatment for COVID-19 on Wednesday. "Today''s authorization provides an additional treatment option against the COVID-19 virus in the form of a pill that can be taken orally," Dr. Patrizia Cavazzoni, director of the FDA''s Center for Drug Evaluation and Research, said Thursday. "Molnupiravir is limited to situations where other FDA-authorized treatments for COVID-19 are inaccessible or are not clinically appropriate and will be a useful treatment option for some patients with COVID-19 at high risk of hospitalization or death," she added.